Michael J Goodman1, Mehul Jhaveri2, Kim Saverno3, Kellie Meyer4, Brian Nightengale5. 1. Director, Xcenda, Palm Harbor, FL. 2. Manager, Health Outcomes, sanofi-aventis, Bridgewater, NJ. 3. PhD student in Pharmaceutical Economics, Policy, and Outcomes, University of Arizona College of Pharmacy, Tucson, AZ, and an analyst, Xcenda, Palm Harbor, FL. 4. Associate Director, Xcenda, Palm Harbor, FL. 5. Vice President, Xcenda, Palm Harbor, FL.
Abstract
OBJECTIVE: Allergic rhinitis imposes a significant health and economic burden both on individuals and the healthcare system. Second-generation prescription antihistamines, levocetirizine, fexofenadine, and desloratadine, and the leukotriene receptor antagonist, montelukast, differ in their ability to relieve common rhinitis symptoms. The purpose of this study was to compare the cost-effectiveness of prescription agents based on their effectiveness in relieving nasal symptoms. METHODS: Effectiveness was measured as the composite of nasal symptoms, including congestion, rhinorrhea, and sneezing, from clinical studies that compared each of the 4 comparators to placebo. Direct costs included prescription therapy and rhinitis-related physician office visits. Physician office visit costs were collected from an analysis of the PharMetrics insurance claims database. Sensitivity analyses were conducted using a Monte Carlo simulation to assess the robustness of the average and incremental cost-effectiveness ratios. RESULTS: The cost per clinically significant improvement of nasal symptoms for levocetirizine was less than for the other model comparator agents. The incremental cost-effectiveness ratio for levocetirizine dominated montelukast and desloratadine and was lower than either branded or generic fexofenadine. CONCLUSION: Levocetirizine is a cost-effective therapy for the relief of nasal symptoms of allergic rhinitis.
OBJECTIVE:Allergic rhinitis imposes a significant health and economic burden both on individuals and the healthcare system. Second-generation prescription antihistamines, levocetirizine, fexofenadine, and desloratadine, and the leukotriene receptor antagonist, montelukast, differ in their ability to relieve common rhinitis symptoms. The purpose of this study was to compare the cost-effectiveness of prescription agents based on their effectiveness in relieving nasal symptoms. METHODS: Effectiveness was measured as the composite of nasal symptoms, including congestion, rhinorrhea, and sneezing, from clinical studies that compared each of the 4 comparators to placebo. Direct costs included prescription therapy and rhinitis-related physician office visits. Physician office visit costs were collected from an analysis of the PharMetrics insurance claims database. Sensitivity analyses were conducted using a Monte Carlo simulation to assess the robustness of the average and incremental cost-effectiveness ratios. RESULTS: The cost per clinically significant improvement of nasal symptoms for levocetirizine was less than for the other model comparator agents. The incremental cost-effectiveness ratio for levocetirizine dominated montelukast and desloratadine and was lower than either branded or generic fexofenadine. CONCLUSION:Levocetirizine is a cost-effective therapy for the relief of nasal symptoms of allergic rhinitis.
Authors: D I Bernstein; W F Schoenwetter; R A Nathan; W Storms; R Ahlbrandt; J Mason Journal: Ann Allergy Asthma Immunol Date: 1997-11 Impact factor: 6.347
Authors: Charles E Lamb; Paul H Ratner; Clarion E Johnson; Ambarish J Ambegaonkar; Ashish V Joshi; David Day; Najah Sampson; Benjamin Eng Journal: Curr Med Res Opin Date: 2006-06 Impact factor: 2.580
Authors: Paul Chervinsky; George Philip; Marie-Pierre Malice; Jose Bardelas; Anjuli Nayak; Jean-Louis Marchal; Janet van Adelsberg; Jean Bousquet; Carol A Tozzi; Theodore F Reiss Journal: Ann Allergy Asthma Immunol Date: 2004-03 Impact factor: 6.347
Authors: Shelley R Berson; Jaclyn Klimczak; Elizabeth A Prezio; Shirley Hu; Manoj Abraham Journal: Int Forum Allergy Rhinol Date: 2018-02-20 Impact factor: 3.858
Authors: Olavo de Godoy Mion; João Ferreira de Mello; Daniel Lorena Dutra; Nilvano Alves de Andrade; Washington Luiz de Cerqueira Almeida; Wilma Teresinha Anselmo-Lima; Leonardo Lopes Balsalobre Filho; Jair de Carvalho E Castro; Roberto Eustáquio Dos Santos Guimarães; Marcus Miranda Lessa; Sérgio Fabrício Maniglia; Roberto Campos Meireles; Márcio Nakanishi; Shirley Shizue Nagata Pignatari; Renato Roithmann; Fabrizio Ricci Romano; Rodrigo de Paula Santos; Marco César Jorge Dos Santos; Edwin Tamashiro Journal: Braz J Otorhinolaryngol Date: 2017-01-21